Navigation Links
MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents
Date:11/6/2008

GERMANTOWN, Md., Nov. 6 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that three patents protecting Moxatag (amoxicillin extended-release) Tablets, 775mg, were listed in the FDA Orange Book on Oct. 24, 2008, pursuant to Section 4 of Public Law No. 110-379, which was enacted on Oct. 8, 2008.

MiddleBrook President & CEO John Thievon said, "Public Law No. 110-379 provides important incentives for drug developers to innovate in the antibiotic arena. MiddleBrook has already made progress in this therapeutic class with Moxatag, the first and only FDA-approved once-daily amoxicillin. We believe that Moxatag addresses significant unmet needs in the antibiotic therapeutic area through patient convenience and a lower overall dose."
MiddleBrook Pharmaceuticals Reports Inducement Grants

Under NASDAQ Marketplace Rule 4350 MiddleBrook Pharmaceuticals also announced today that on Oct. 31, 2008, it granted options to purchase 584,000 shares of MiddleBrook's common stock to four (4) new employees as a material inducement for them to join MiddleBrook. The options were granted pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) and under MiddleBrook's New Hire Stock Incentive Plan, which was approved by MiddleBrook's Board of Directors on Sept. 26, 2008. The options have a per share exercise price equal to the closing price of MiddleBrook's common stock on the NASDAQ Global Market on the day immediately preceding the grant date, a ten-year term and vesting over four years, with 25 percent of the options vesting one year from the grant date and 1/48th of the opti
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
2. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
3. MiddleBrook to Webcast Management Presentation at the 10th Annual Rodman & Renshaw Healthcare Conference
4. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
5. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
6. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
7. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
8. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
9. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
10. Webcast Alert: Isis Pharmaceuticals Cardiovascular Program Review
11. Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area 2Health News:The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area 3Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 2Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 3Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 2Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 3Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 4Health News:Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn 2Health News:Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn 3Health News:Sticks and stones break bones, but this UH study may prevent it 2
Breaking Medicine Technology:St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3Al Novak Elected Chairman of the Board of OrbusNeich Medical 2SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology 2SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology 3EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 1EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 2EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 3Spectral announces publication demonstrating Toraymyxin 28TM 29 significantly reduces mortality from sepsis in prospective controlled trial 12688 1Spectral announces publication demonstrating Toraymyxin 28TM 29 significantly reduces mortality from sepsis in prospective controlled trial 12688 2Spectral announces publication demonstrating Toraymyxin 28TM 29 significantly reduces mortality from sepsis in prospective controlled trial 12688 3Ovu Trac 28R 29 Home Test Kit From OvumOptics Predicts Ovulation with 96 2 25 Accuracy 49321 1Ovu Trac 28R 29 Home Test Kit From OvumOptics Predicts Ovulation with 96 2 25 Accuracy 49321 2Ovu Trac 28R 29 Home Test Kit From OvumOptics Predicts Ovulation with 96 2 25 Accuracy 49321 3Ovu Trac 28R 29 Home Test Kit From OvumOptics Predicts Ovulation with 96 2 25 Accuracy 49321 4